US2006140951A1PendingUtilityA1

Tumour necrosis factor binding ligands

70
Individually held — no corporate assignee on recordPriority: Aug 7, 1989Filed: Feb 22, 2006Published: Jun 29, 2006
Est. expiryAug 7, 2009(expired)· nominal 20-yr term from priority
Inventors:Deborah RathjenRoger Aston
A61K 47/6813A61K 47/68A61K 38/00C07K 2317/73C07K 16/241C07K 2317/55C07K 2317/622C07K 2317/24C07K 2317/75C07K 2317/21C07K 2319/00A61P 35/00C07K 2317/76
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94 (peptide 309) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 73-94. Antibodies or fragments thereof which bind particular regions of mature human TNF-α are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or fragment thereof which binds a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94  (peptide 309) of mature human TNF-α.  
   
   
       2 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a monoclonal antibody.  
   
   
       3 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a chimeric antibody.  
   
   
       4 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a humanized antibody.  
   
   
       5 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a human antibody.  
   
   
       6 . A composition comprising an isolated antibody or fragment thereof which binds a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94  (peptide 309) of mature human TNF-α.  
   
   
       7 . A composition according to  claim 6 , wherein the antibody is a monoclonal antibody.  
   
   
       8 . A composition according to  claim 6 , wherein the antibody is a chimeric antibody.  
   
   
       9 . A composition according to  claim 6 , wherein the antibody is a humanized antibody.  
   
   
       10 . A composition according to  claim 6 , wherein the antibody is a human antibody.  
   
   
       11 . An isolated single chain antibody which binds a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94  (peptide 309) of mature human TNF-α.  
   
   
       12 . An antibody according to  claim 11 , wherein the antibody is a monoclonal antibody.  
   
   
       13 . An antibody according to  claim 11 , wherein the antibody is a chimeric antibody.  
   
   
       14 . An antibody according to  claim 11 , wherein the antibody is a humanized antibody.  
   
   
       15 . An antibody according to  claim 11 , wherein the antibody is a human antibody.  
   
   
       16 . A composition comprising an isolated single chain antibody which binds a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94  (peptide 309) of mature human TNF-α.  
   
   
       17 . A composition according to  claim 16 , wherein the antibody is a monoclonal antibody.  
   
   
       18 . A composition according to  claim 16 , wherein the antibody is a chimeric antibody.  
   
   
       19 . A composition according to  claim 16 , wherein the antibody is a humanized antibody.  
   
   
       20 . A composition according to  claim 16 , wherein the antibody is a human antibody.  
   
   
       21 . An isolated single domain antibody or fragment thereof which binds a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94  (peptide 309) of mature human TNF-α.  
   
   
       22 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a monoclonal antibody.  
   
   
       23 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a chimeric antibody.  
   
   
       24 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a humanized antibody.  
   
   
       25 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a human antibody.  
   
   
       26 . A composition comprising an isolated single domain antibody or fragment thereof which binds a peptide consisting of residues His 73 -Val 74 -Leu 75 -Leu 76 -Thr 77 -His 78 -Thr 79 -Ile 80 -Ser 81 -Arg 82 -Ile 83 -Ala 84 -Val 85 -Ser 86 -Tyr 87 -Gln 88 -Thr 89 -Lys 90 -Val 91 -Asn 92 -Leu 93 -Leu 94  (peptide 309) of mature human TNF-α.  
   
   
       27 . A composition according to  claim 26 , wherein the antibody is a monoclonal antibody.  
   
   
       28 . A composition according to  claim 26 , wherein the antibody is a chimeric antibody.  
   
   
       29 . A composition according to  claim 26 , wherein the antibody is a humanized antibody.  
   
   
       30 . A composition according to  claim 26 , wherein the antibody is a human antibody.

Join the waitlist — get patent alerts

Track US2006140951A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.